Graduate Studies Faculty

« Back to Search List

Alexey V. Danilov, M.D., Ph.D.

Assistant Professor
Admin Unit: The Knight Cancer Institute
Phone: 503-494-8426
Office: BDB523
Cancer Biology
Research Interests:
Preceptor Rotations
Dr. Danilov has not indicated availability for preceptor rotations at this time.
Faculty Mentorship
Dr. Danilov has not indicated availability as a mentor at this time.

Dr Danilov's laboratory investigates mechanisms of drug resistance in B-cell malignancies. Lymph nodes and bone marrow are sites where neoplastic B-cells are exposed to cellular and acellular components of the microenvironment, which deliver pro-survival stimuli. Dr. Danilov’s laboratory has a particular focus on the role of tumor necrosis factor family receptors and nuclear factor-kappaB signaling in this setting, and how this signaling can be targeted. In addition to a variety of in vitro models of the stromal niche, Dr. Danilov’s laboratory models those conditions in vivo. Most recently, his laboratory has identified several promising strategies to inhibit stromal niche support via targeting proteasome-ubiquitin system responsible for protein degradation. Dr. Danilov’s research is highly translational and involves work with primary samples from patients with CLL and lymphoma. Based on laboratory findings, Dr. Danilov's group originates early-phase clinical trials, allowing for verification of laboratory findings in the clinical setting. Dr. Danilov and his group present their work annually at the American Society of Hematology Meeting, as well as at specialty group meetings.


Paiva C, Godbersen JC, Soderquist R, Rowland T, Sumner K, Spurgeon SE, Brown JR, Srinivasa SP and Danilov AV. 2015. CDK inhibior P1446A induces apoptosis in a JNK/p38MAPK-dependent manner in Chronic Lymphocytic Leukemia B-cells. PLoS One. 10(11): e0143685.

 Paiva C, Godbersen JC, Berger A, Brown JR and Danilov AV. 2015. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B-cells to the alkylating agents. Cell Death and Disease. 6: e1807.

Hu S, Danilov AV et al. 2015. CDK2 inhibition causes anaphase catastrophe in lung cancer through the Centrosomal protein CP110. Cancer Research. 75(10): 2029-2038.

Godbersen JC, Paiva C, Danilova OV, Berger A, Brown JR and Danilov AV. 2015.Targeting neddylation effectively antagonizes NFkB in chronic lymphocytic leukemia (CLL) B-cells. Leukemia & Lymphoma. In press (Invited manuscript)

 Danilova OV, Paiva C, Kaur P, Kamal A, Sempere LF and Danilov AV. 2015. microRNA-21 is differentially expressed in the lymphoid tissue and modulated by stromal signaling in chronic lymphocytic leukemia. British Journal of Haematology. In press

 Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A and Danilov AV.2014.The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-kB activation and induces apoptosis in chronic lymphocytic leukemia B-cells. Clinical Cancer Research.20 (6): 1576-1589.

 Soderquist R, Danilov AVand Eastman A. 2014. Gossypol increases expression of the pro-apoptotic BH3-only protein NOXA through a novel mechanism involving phospholipase A2, cytoplasmic calcium and endoplasmic reticulum stress. Journal of Biological Chemistry. 289(23):16190-16199.

 Soderquist R, Pletnev AA, Danilov AVand Eastman A. 2014.The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA. Apoptosis. 19(1): 201-209.

 Humphries LA, Godbersen JC, Danilova OV, Kaur P, Christensen B and Danilov AV.2013.Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signaling in chronic lymphocytic leukemia. British Journal of Haematology.163 (5): 590-602.

 Bates D, Danilov AV, Lowrey CH and Eastman A. 2013. Vinblastine rapidly induces Noxa and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737. Molecular Cancer Therapeutics.12(8):1504-1514.

 Soderquist R, Bates D, Danilov AV and Eastman A. 2013. Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo. Leukemia. 27 (11): 2262-2264.

 Danilova OV, Dumont LJ, Levy NB, Lansigan F, Kinlaw WB and Danilov AVand Kaur P.  2013.FASN and CD36 predict survival in rituximab treated diffuse large B-cell lymphoma. Journal of Hematopathology.6 (1): 11-18.

 Danilov AV, Neupane DN, Nagaraja AS, Feofanova EV, Humphries LA, Direnzo J and Korc M. 2011.DNp63apromotes oncogenesis in pancreatic cancer via trans-activation of epidermal growth factor receptor. PLoS One. 6(10):e26815.

 Danilov AV, Danilova OV, Brown J, Rabinowitz A, Klein AK and Huber BT. 2010. Dipeptidyl Peptidase-2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. Experimental Hematology. 38 (12): 1167-1177.

 Danilov AV, Klein AK, Lee HJ, Velez Baez D, Huber BT.  2005. Differential control of G0program in chronic lymphocytic leukemia: a novel prognostic factor. British Journal of Haematology.128: 472-481.



Manda S, Dunbar NM, Marx-Wood CR and Danilov AV. 2015. Ibrutinib is an effective treatment of autoimmune hemolytic anemia in CLL. British Journal of Haematology. In press.

 Shindiapina P, Brown JR and Danilov AV. 2014.A new hope: Novel therapeutic approaches to treatment of chronic lymphocytic leukemia with defects in TP53. British Journal of Haematology. 167 (2): 149-161.

 Sullivan MR, Danilov AV, Lansigan F and Dunbar NM. 2014. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. Journal of Clinical Apheresis. doi: 10.1002/jca.21371

 Danilov AV. 2013. Targeted therapy in chronic lymphocytic leukemia: past, present and future. Clinical Therapeutics. 35(9): 1258-1270.

 Danilov AV, Soderquist R, Bates D and Eastman A. 2013.Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts. Expert Review in Anticancer Therapy. 13(9): 1009-1012.

 Holderness BM, Malhotra S, Levy NB and Danilov AV. 2013. Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia. Journal of Clinical Oncology. 31(12): e197-199.